SEGMENT - Schedule of Disaggregated Expense Information Included in the Consolidated Statements of Comprehensive Loss (Details) - USD ($) $ in Thousands |
6 Months Ended | |
|---|---|---|
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Segment research and development expenses: | ||
| Segment administrative expenses | $ 8,309 | $ 14,378 |
| Net loss | (8,654) | 9,106 |
| Segment | ||
| Segment research and development expenses: | ||
| Direct clinical development expenses | 189 | 5,776 |
| Employee-related expenses | 2,775 | 3,730 |
| Other research and development expenses | 1,107 | 1,759 |
| Segment administrative expenses | 8,309 | 14,378 |
| Other segment items | (3,726) | (7,283) |
| Net loss | $ (8,654) | $ (18,360) |
| X | ||||||||||
- Definition Direct clinical development expenses No definition available.
|
| X | ||||||||||
- Definition R and D personnel costs. No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|